Nanobiotix S.A. was incorporated as an anonymous company on March 4, 2003. The company is a clinical-stage biotechnology company focused on developing best-in-class product candidates that leverage its proprietary nanotechnology to transform cancer treatment by improving the efficacy of radiation therapy. Their main product candidate, NBTXR3, is a water suspension of functionalized crystalline hafnium oxide nanoparticles designed to be injected directly into malignant tumors prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 amplifies the localized intratumoral killing effect of radiation and may also stimulate the body's immune response to fight cancer. NBTXR3 is designed to improve the overall efficacy of radiotherapy without additional side effects on surrounding healthy tissue.